Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. (Record no. 29581043)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01427 a2200421 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518033508.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 202002s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 2052-1707 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1002/prp2.473 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Rosebraugh, Matthew |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20200224 |
| 245 00 - TITLE STATEMENT | |
| Title | Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Pharmacology research & perspectives |
| Date of publication, distribution, etc. | 04 2019 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | e00473 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antiparkinson Agents |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Carbidopa |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cross-Over Studies |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Combinations |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Liberation |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gels |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Levodopa |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Therapeutic Equivalency |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kalluri, Hari V |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Liu, Wei |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Locke, Charles |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sidhu, Dilraj |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Han, Jian-Hwa |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Benesh, Janet |
| 773 0# - HOST ITEM ENTRY | |
| Title | Pharmacology research & perspectives |
| Related parts | vol. 7 |
| -- | no. 2 |
| -- | p. e00473 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1002/prp2.473">https://doi.org/10.1002/prp2.473</a> |
| Public note | Available from publisher's website |
No items available.